September 18, 2019
Versantis closes CHF 16M series B financing round to advance clinical development of novel therapeutics for liver diseases
Versantis has closed a series B financing round, and plans to use the funds to fuel the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.